Omeros Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
175
- Stock Symbol
-
OMER
- Investments
-
2
- Share Price
-
$17.49
- (As of Friday Closing)
Omeros General Information
Description
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Contact Information
Website
www.omeros.comCorporate Office
- The Omeros Building
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Corporate Office
- The Omeros Building
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Omeros Timeline
Omeros Stock Performance
As of 13-Nov-2026, Omeros’s stock price is $17.49. Its current market cap is $1.27B with 72.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.49 | $17.99 | $6.59 - $21.24 | $1.27B | 72.4M | 1.37M | $1.71 |
Omeros Financials Summary
As of 30-Jun-2026, Omeros has a trailing 12-month revenue of $38.4M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 701,820 | 1,373,239 | 658,858 | 236,134 |
| Revenue | 38,422 | 0 | 0 | 0 |
| EBITDA | 120,554 | (6,852) | (165,934) | (159,498) |
| Net Income | 124,826 | (3,350) | (156,815) | (117,813) |
| Total Assets | 286,833 | 325,632 | 277,079 | 378,269 |
| Total Debt | 138,989 | 239,143 | 207,020 | 236,458 |
Omeros Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Omeros Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Omeros Comparisons
Industry
Financing
Details
Omeros Competitors (54)
One of Omeros’s 54 competitors is Alzheon, a Venture Capital-Backed company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA |
Omeros Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Omeros Patents
Omeros Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260297152-A1 | Methods and compositions for treating cancer | Pending | 31-Mar-2025 | ||
| WO-2026213059-A1 | Methods and compositions for treating cancer | Pending | 31-Mar-2025 | ||
| WO-2026169606-A1 | Targeted complement activating molecules and methods of use thereof | Pending | 04-Feb-2025 | ||
| US-20250122225-A1 | Masp-2 inhibitors and methods of use | Pending | 06-Oct-2023 | ||
| WO-2025076476-A2 | Masp-2 inhibitors and methods of use | Inactive | 06-Oct-2023 | C07D519/00 |
Omeros Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Omeros Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Omeros Acquisitions (2)
Omeros’s most recent deal was a Merger/Acquisition with Patobios (GPCR Assay Technology) for . The deal was made on 22-Nov-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Patobios (GPCR Assay Technology) | 22-Nov-2010 | Merger/Acquisition | Buildings and Property | ||
| Nura (USA) | 07-Sep-2006 | Merger/Acquisition | Drug Discovery |
Omeros ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.54 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Omeros FAQs
-
When was Omeros founded?
Omeros was founded in 1994.
-
Where is Omeros headquartered?
Omeros is headquartered in Seattle, WA.
-
What is the size of Omeros?
Omeros has 175 total employees.
-
What industry is Omeros in?
Omeros’s primary industry is Biotechnology.
-
Is Omeros a private or public company?
Omeros is a Public company.
-
What is Omeros’s stock symbol?
The ticker symbol for Omeros is OMER.
-
What is the current stock price of Omeros?
As of 13-Nov-2026 the stock price of Omeros is $17.49.
-
What is the current market cap of Omeros?
The current market capitalization of Omeros is $1.27B.
-
What is Omeros’s current revenue?
The trailing twelve month revenue for Omeros is $38.4M.
-
Who are Omeros’s competitors?
Alzheon, Cognition Therapeutics, Vertex Pharmaceuticals, Seres Therapeutics, and Vedanta Biosciences are some of the 54 competitors of Omeros.
-
What is Omeros’s annual earnings per share (EPS)?
Omeros’s EPS for 12 months was $1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
